SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Taro Pharmaceutical Industries Ltd. - TARO

NEW YORK, Oct. 20, 2016

The investigation concerns whether Taro and certain of its officers and/or directors have violated the federal securities laws.

[Click here to join a class action]

On September 9, 2016, Taro disclosed that the Company and two of its senior officers had received grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing.

On this news, Taro's share price fell $4.94, or 3.97%, to close at $119.42 per share on September 12, 2016, the next trading day.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com